Acquiring Company
Novo Nordisk
Acquired Company
Akero Therapeutics
Denmark
South San FranciscoManufacturingScience And EngineeringBiotechnologyHealth CareTherapeuticsDescription
Novo Nordisk has finalized its acquisition of Akero Therapeutics for 54 USD per share, equating to a total value of 4.7 billion USD. Akero will now operate as a wholly owned subsidiary of Novo Nordisk, and its common stock will no longer be listed on Nasdaq. This acquisition aims to enhance Novo Nordisk's capabilities in treating chronic diseases.
Quick answer
Novo Nordisk is acquiring Akero Therapeutics, announced December 9, 2025. Novo Nordisk is based in Denmark.
- How much did Novo Nordisk pay for Akero Therapeutics?
- The deal value was not disclosed.
- What does Novo Nordisk do?
- Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
- Where are Novo Nordisk and Akero Therapeutics based?
- Novo Nordisk is based in Denmark. Akero Therapeutics is based in South San Francisco, California, United States.
- Who are the decision-makers at Novo Nordisk?
- Fundz holds 2 contacts at Novo Nordisk. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Science And Engineering and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Revolution Medicines soon (January 9, 2026)
- Pfizer completes $43 billion acquisition of Seagen, $43B (January 4, 2026)
- BioNTech completes acquisition of CureVac (December 20, 2025)
- BioMarin to acquire Amicus for $4.8 billion, $4.8B (December 19, 2025)
- Perceptive Capital to merge with Freenome Holdings (December 5, 2025)
- Day One to acquire Mersana for $130 million, $130M (November 30, 2025)
Who to call at Novo Nordisk, and when
When Novo Nordisk changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Novo Nordisk raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novo Nordisk, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novo Nordisk. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Novo Nordisk makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Akero Therapeutics?
Akero Therapeutics was acquired by Novo Nordisk, based in Denmark. The deal was reported on December 9, 2025. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Novo Nordisk is privately held and operates in Manufacturing.
When did Novo Nordisk acquire Akero Therapeutics?
Novo Nordisk's acquisition of Akero Therapeutics was reported on December 9, 2025. Novo Nordisk has finalized its acquisition of Akero Therapeutics for 54 USD per share, equating to a total value of 4.7 billion USD. Akero will now operate as a wholly owned subsidiary of Novo Nordisk, and its common stock will no longer be listed on Nasdaq. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Akero Therapeutics do?
Akero Therapeutics, Inc. is a clinical-stage company developing transformational treatments for patients with serious metabolic disease. It is privately held, operating in Biotechnology, and is based in South San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.